Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms
- PMID: 22771991
- PMCID: PMC3654764
- DOI: 10.4161/trns.20496
Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms
Abstract
Although multiple cellular mechanisms have been proposed to explain endocrine resistance in breast cancer, the genomics events promoting the dysregulation of gene expression pattern are not clearly understood. Because chromatin plays a dynamic role in the estrogen receptor α (ERα) transcriptional program, we herein review signaling pathways implicated in endocrine resistance and try to merge them with recent epigenetic studies.
Figures

Similar articles
-
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.Mol Cancer. 2024 Aug 7;23(1):160. doi: 10.1186/s12943-024-02071-2. Mol Cancer. 2024. PMID: 39113071 Free PMC article.
-
Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.Breast Cancer Res Treat. 2020 Feb;180(1):45-54. doi: 10.1007/s10549-019-05517-0. Epub 2020 Jan 2. Breast Cancer Res Treat. 2020. PMID: 31897900 Free PMC article.
-
Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.Steroids. 2016 Oct;114:41-47. doi: 10.1016/j.steroids.2016.06.007. Epub 2016 Jul 6. Steroids. 2016. PMID: 27394959 Review.
-
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.Oncogene. 2009 Jan 29;28(4):575-86. doi: 10.1038/onc.2008.405. Epub 2008 Nov 10. Oncogene. 2009. PMID: 18997820 Free PMC article.
-
Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.Acta Oncol. 1996;35 Suppl 5:9-14. doi: 10.3109/02841869609083961. Acta Oncol. 1996. PMID: 9142958 Review.
Cited by
-
OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.Oncogene. 2016 Nov 3;35(44):5722-5734. doi: 10.1038/onc.2016.105. Epub 2016 Apr 11. Oncogene. 2016. PMID: 27065334
-
Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.Cell Oncol (Dordr). 2020 Feb;43(1):65-80. doi: 10.1007/s13402-019-00439-x. Epub 2019 Nov 7. Cell Oncol (Dordr). 2020. PMID: 31701491
-
Multidrug-resistant breast cancer: current perspectives.Breast Cancer (Dove Med Press). 2014 Jan 10;6:1-13. doi: 10.2147/BCTT.S37638. eCollection 2014. Breast Cancer (Dove Med Press). 2014. PMID: 24648765 Free PMC article. Review.
-
LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression.Oncogene. 2015 Aug 20;34(34):4509-18. doi: 10.1038/onc.2014.382. Epub 2014 Dec 1. Oncogene. 2015. PMID: 25435372
-
Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer.Breast Cancer (Auckl). 2020 Dec 16;14:1178223420976387. doi: 10.1177/1178223420976387. eCollection 2020. Breast Cancer (Auckl). 2020. PMID: 33402826 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical